Skip to content

Analysis of risk factors of preeclampsia based on detection of cell-free DNA methylation in maternal peripheral blood

Analysis of risk factors of preeclampsia based on detection of cell-free DNA methylation in maternal peripheral blood

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064509
Enrollment
Unknown
Registered
2022-10-10
Start date
2022-10-05
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

Group 1 :
Group 2:

Sponsors

The Second People's Hospital of Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Preeclampsia group: (1) Systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg in pregnant women after 20 weeks of gestation, accompanied by any one of the following: quantitative urine protein >= 0.3 g/24h, or urine protein/creatinine ratio >= 0.3, or random urine protein >= (+) (examination method when protein quantification is unconditional); no proteinuria but with any one of the following organ or system involvement: heart, lung, liver, kidney and other vital organs, or blood system, digestive system, nerve Abnormal changes in the system, the placenta-fetus is involved, etc.; (2) Single birth; (3) Sign the informed consent form; 2. Control group: (1) No occurrence of hypertensive disorders during pregnancy; (2) Single birth; (3) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Multiple pregnancy; 2. Malignant tumors; 3. Pregnant women have received blood transfusion within 8 weeks of blood collection; 4. History of organ transplantation or bone marrow transplantation; 5. Fetal chromosomal abnormalities or intrauterine death; 6. Severe fetal malformation; 7. Using chronic steroids or immunosuppressive drugs; 8. Severe autoimmune diseases, antiphospholipid syndrome; 9. Gestational diabetes, severe liver and kidney, heart disease.

Design outcomes

Primary

MeasureTime frame
2-4 methylation regions in cfDNA between the two groups;

Secondary

MeasureTime frame
Age of pregnant woman;Body mass index;

Countries

China

Contacts

Public ContactKe Weilin

Shenzhen Second People’s Hospital

szkeweihengd@126.com+86 13714639891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026